Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Keith Demarest"'
Autor:
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Marcus Hompesch, Sabine Arnolds, Linda Morrow, Heike Spitzer, Keith Demarest, Paul Rothenberg
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105638 (2014)
This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes.
Externí odkaz:
https://doaj.org/article/702046dc63b143b9a12cc8bdb0fc7c0f
Autor:
Yin Liang, Kenji Arakawa, Kiichiro Ueta, Yasuaki Matsushita, Chiaki Kuriyama, Tonya Martin, Fuyong Du, Yi Liu, June Xu, Bruce Conway, Jamie Conway, David Polidori, Kirk Ways, Keith Demarest
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e30555 (2012)
BACKGROUND: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM). METHODS: (14)C-alpha-methylglucoside uptake in Chinese hamster ovary-K cells expressing huma
Externí odkaz:
https://doaj.org/article/df414787d96e4b259c141d5ae76d36f9
Autor:
Yue-Mei, Zhang, Michael, Greco, Tonya, Le Blanc, Wensheng, Lang, Jack, Kauffman, John, Masucci, William V, Murray, Keith, Demarest, Mark Joseph, Macielag
Publikováno v:
ACS Med Chem Lett
[Image: see text] The 6-benzhydryl-4-amino-quinolin-2-ones are peripherally restricted CB(1) receptor inverse agonists (CB(1)RIAs) that have been reported to attenuate obesity and improve insulin sensitivity in the diet-induced obese (DIO) mouse mode
Autor:
Yue-Mei, Zhang, Michael N, Greco, Mark J, Macielag, Christopher A, Teleha, Renee L, DesJarlais, Yuting, Tang, George, Ho, Cuifen, Hou, Cailin, Chen, Shuyuan, Zhao, Jack, Kauffman, Raul, Camacho, Jenson, Qi, William, Murray, Keith, Demarest, James, Leonard
Publikováno v:
Journal of medicinal chemistry. 61(22)
A novel series of 6-benzhydryl-4-amino-quinolin-2-ones was discovered as cannabinoid type 1 receptor (CB
Autor:
Mary L. Holland, Keith Demarest, Phillip C. Greig, Jorge P. Figueroa, Raymond C. Weglein, G. Angela Massmann
Publikováno v:
American Journal of Obstetrics and Gynecology. 169:897-902
Objectives: Atosiban is a synthetic oxytocin antagonist that is currently undergoing dose-ranging clinical trials. To date, no data are available on the cardiovascular effects of combined oxytocin and vasopressin blockade during late pregnancy. Our a
Autor:
Lan Shen, Yan Zhang, Aihua Wang, Ellen Sieber-McMaster, Xiaoli Chen, Patricia Pelton, Jun Z. Xu, Maria Yang, Peifang Zhu, Lubing Zhou, Michael Reuman, Zhiyong Hu, Ronald Russell, Alan C. Gibbs, Hamish Ross, Keith Demarest, William V. Murray, Gee-Hong Kuo
Publikováno v:
Journal of Medicinal Chemistry; Aug2007, Vol. 50 Issue 16, p3954-3963, 10p
Publikováno v:
Molecular & Cellular Biochemistry; Jan2007, Vol. 294 Issue 1, p243-248, 6p
Publikováno v:
Journal of Pharmacy & Pharmacology; May2003, Vol. 55 Issue 5, p631-637, 7p
Publikováno v:
Scopus-Elsevier
To investigate whether a putative oxytocin (OT) receptor blocker 1-deamino-[2-D-tyrosine (OEt)-4 threonine-8-ornithine]oxytocin (dTVT) inhibits OT binding to its receptors, we studied binding of [3H]OT to late-pregnant human, guinea pig, and rat myom
Publikováno v:
American journal of obstetrics and gynecology. 161(6 Pt 1)
Saturation analysis and competition experiments were performed to identify and characterize [ 3 H]arginine vasopressin binding to human myometrium and decidua in late pregnancy. [ 3 H]Arginine vasopressin bound with affinity similar to that of [ 3 H]